{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:58:58Z","timestamp":1776448738516,"version":"3.51.2"},"reference-count":90,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ucl.2026.02.014","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:50:30Z","timestamp":1773319830000},"page":"331-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatments on the Horizon for Men with Advanced Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Matthew I.","family":"Ehrlich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron S.","family":"Gejman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezra","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark N.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2026.02.014_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/11795549241227413","article-title":"Characterization and survival benefit of drug approvals for metastatic prostate cancer, 2004 to 2022","volume":"18","author":"Benjamin","year":"2024","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.ucl.2026.02.014_bib4","article-title":"Systemic treatment options for metastatic castration resistant prostate cancer: a living systematic review","author":"Naqvi","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.ucl.2026.02.014_bib5","doi-asserted-by":"crossref","first-page":"S1175","DOI":"10.1016\/j.annonc.2022.07.1516","article-title":"1384P treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2010 to 2019","volume":"33","author":"George","year":"2022","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.ucl.2026.02.014_bib6","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/pros.22504","article-title":"Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar Androgen Therapy (BAT) for castrate resistant human prostate cancer","volume":"72","author":"Isaacs","year":"2012","journal-title":"Prostate"},{"issue":"10","key":"10.1016\/j.ucl.2026.02.014_bib7","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1172\/JCI127613","article-title":"Supraphysiological androgens suppress prostate cancer growth through androgen receptor\u2013mediated DNA damage","volume":"129","author":"Chatterjee","year":"2019","journal-title":"J Clin Investig"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.014_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/oncolo\/oyad055","article-title":"Bipolar androgen therapy followed by androgen receptor inhibition as sequential therapy for prostate cancer","volume":"28","author":"Denmeade","year":"2023","journal-title":"Oncologist"},{"issue":"269","key":"10.1016\/j.ucl.2026.02.014_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010563","article-title":"Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study","volume":"7","author":"Schweizer","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.014_bib10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.eururo.2020.06.042","article-title":"A multicohort open-label phase II trial of bipolar androgen therapy in men with metastatic castration-resistant prostate cancer (RESTORE): a comparison of post-abiraterone versus post-enzalutamide cohorts","volume":"79","author":"Markowski","year":"2021","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.014_bib11","first-page":"1371","article-title":"TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer","volume":"39","author":"Denmeade","year":"2021","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.014_bib12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41467-023-44514-2","article-title":"Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial","volume":"15","author":"Markowski","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.014_bib13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41391-022-00636-0","article-title":"Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer","volume":"26","author":"Schweizer","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.02.014_bib14","first-page":"218","article-title":"A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study)","volume":"43","author":"Crumbaker","year":"2025","journal-title":"J Clin Orthod"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.02.014_bib15","first-page":"178","article-title":"Extreme bipolar androgen therapy: alternating darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer (mCRPC; ExBAT trial\/LACOG 0620)","volume":"43","author":"Isaacsson","year":"2025","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.014_bib16","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300171","article-title":"Targeted inhibition of CYP11A1 in castration-resistant prostate cancer","volume":"3","author":"Fizazi","year":"2024","journal-title":"NEJM Evid"},{"issue":"4_suppl","key":"10.1016\/j.ucl.2026.02.014_bib17","first-page":"159","article-title":"MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results","volume":"42","author":"Fizazi","year":"2024","journal-title":"J Clin Orthod"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.02.014_bib18","first-page":"TPS286","article-title":"OMAHA-003: a phase 3 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy","volume":"43","author":"Yu","year":"2025","journal-title":"J Clin Orthod"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.02.014_bib19","first-page":"TPS301","article-title":"Phase 3 OMAHA-004 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA","volume":"43","author":"Gratzke","year":"2025","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.014_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","article-title":"Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Rathkopf","year":"2025","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib21","first-page":"TPS5119","article-title":"A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator\u2019s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - recharge)","volume":"43","author":"Chi","year":"2025","journal-title":"J Clin Orthod"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.02.014_bib22","first-page":"17","article-title":"Phase 1\/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Gao","year":"2022","journal-title":"J Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib23","first-page":"5011","article-title":"ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): initial results of a phase 1\/2 study","volume":"42","author":"Petrylak","year":"2024","journal-title":"J Clin Orthod"},{"issue":"11","key":"10.1016\/j.ucl.2026.02.014_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103774","article-title":"RIPTACs: a groundbreaking approach to drug discovery","volume":"28","author":"Ma","year":"2023","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.014_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminoncol.2023.09.003","article-title":"PARP inhibitors for prostate cancer","volume":"51","author":"Longoria","year":"2024","journal-title":"Semin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.02.014_bib26","first-page":"LBA16","article-title":"Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Clarke","year":"2023","journal-title":"J Clin Orthod"},{"issue":"9","key":"10.1016\/j.ucl.2026.02.014_bib27","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.02.014_bib28","first-page":"LBA18","article-title":"Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial","volume":"43","author":"Agarwal","year":"2025","journal-title":"J Clin Orthod"},{"issue":"9","key":"10.1016\/j.ucl.2026.02.014_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2217\/fon-2023-0526","article-title":"TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer","volume":"20","author":"Agarwal","year":"2024","journal-title":"Future Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib30","first-page":"TPS5123","volume":"42","author":"Chi","year":"2024","journal-title":"J Clin Orthod"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.014_bib31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5483\/BMBRep.2022.55.12.174","article-title":"The role of EZH1 and EZH2 in development and cancer","volume":"55","author":"Lee","year":"2022","journal-title":"BMB Rep"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.02.014_bib32","first-page":"TPS288","article-title":"Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate: the phase 3, randomized MEVPRO-1 study","volume":"43","author":"Agarwal","year":"2025","journal-title":"J Clin Orthod"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.02.014_bib33","first-page":"TPS287","article-title":"Mevrometostat (PF-06821497) in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-na\u00efve patients with metastatic castration-resistant prostate cancer (mCRPC): the phase 3, randomized MEVPRO-2 trial","volume":"43","author":"Schweizer","year":"2025","journal-title":"J Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib34","first-page":"TPS5109","article-title":"A phase 1\/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Heath","year":"2024","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ucl.2026.02.014_bib35","first-page":"311","article-title":"Chapter eight - advances in prostate cancer treatment: radionuclide therapy for prostate cancer","volume":"164","author":"Zhong","year":"2024"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.014_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter Radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2026.02.014_bib37","first-page":"TPS5091","article-title":"A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA","volume":"39","author":"Morris","year":"2021","journal-title":"J Clin Orthod"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.02.014_bib38","first-page":"TPS267","article-title":"Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response","volume":"38","author":"Maughan","year":"2020","journal-title":"J Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib39","first-page":"5069","article-title":"A phase l and randomized phase ll trial of radium-223 dichloride, peposertib, and avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC): phase l results","volume":"43","author":"Gay","year":"2025","journal-title":"J Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib40","first-page":"TPS5117","article-title":"A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, an anti-PSMA radioconjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Iagaru","year":"2025","journal-title":"J Clin Orthod"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.02.014_bib41","first-page":"TPS282","article-title":"ACCEL: [Ac-225]-PSMA-62 phase Ia\/Ib\/II clinical trial to characterize efficacy, safety, tolerability, and dosimetry in oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer","volume":"43","author":"Saleh","year":"2025","journal-title":"J Clin Orthod"},{"issue":"7_Supplement","key":"10.1016\/j.ucl.2026.02.014_bib42","doi-asserted-by":"crossref","first-page":"CT224","DOI":"10.1158\/1538-7445.AM2024-CT224","article-title":"Abstract CT224: preliminary efficacy and safety results from the (TATCIST) trial: a PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)","volume":"84","author":"Delpassand","year":"2024","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ucl.2026.02.014_bib43","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: a phase I dose-escalation study of 225Ac-J591","volume":"42","author":"Tagawa","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.02.014_bib44","first-page":"TPS288","article-title":"A phase I\/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA","volume":"41","author":"Nauseef","year":"2023","journal-title":"J Clin Orthod"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.02.014_bib45","first-page":"TPS289","article-title":"CONVERGE-01: dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer","volume":"43","author":"Morris","year":"2025","journal-title":"J Clin Orthod"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.02.014_bib46","first-page":"181","article-title":"Phase I results of a phase I\/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591","volume":"41","author":"Sun","year":"2023","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ucl.2026.02.014_bib47","doi-asserted-by":"crossref","first-page":"S968","DOI":"10.1016\/j.annonc.2024.08.1687","article-title":"1606P mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591","volume":"35","author":"Holmes","year":"2024","journal-title":"Ann Oncol"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.02.014_bib48","first-page":"177","article-title":"CUPID (64Cu-TLX592 phase I PK, biodistribution and dosimetry): a proof-of-concept study of TLX592-targeted alpha therapy in prostate cancer","volume":"43","author":"Lenzo","year":"2025","journal-title":"J Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib49","first-page":"5010","article-title":"A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Morris","year":"2024","journal-title":"J Clin Orthod"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.02.014_bib50","first-page":"TPS275","article-title":"Phase Ib\/IIa dose escalation and expansion study of [212Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: therapb\u2013phase I\/II study","volume":"43","author":"Hansen","year":"2025","journal-title":"J Clin Orthod"},{"issue":"10459","key":"10.1016\/j.ucl.2026.02.014_bib51","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.02.014_bib52","first-page":"TPS278","article-title":"LuCAB: a phase I\/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Kostos","year":"2023","journal-title":"J Clin Orthod"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.02.014_bib53","first-page":"TPS304","article-title":"LuCarbo: a phase 1a\/1b trial of 177Lu-PSMA-617 (LuPSMA) with carboplatin in advanced prostate cancer","volume":"43","author":"Ravi","year":"2025","journal-title":"J Clin Orthod"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.014_bib54","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib55","first-page":"5067","article-title":"Phase 1 study of gotistobart (BNT316\/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Wise","year":"2025","journal-title":"J Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib56","first-page":"5005","article-title":"LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib57","first-page":"TPS5116","article-title":"PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer","volume":"41","author":"Tagawa","year":"2023","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ucl.2026.02.014_bib58","doi-asserted-by":"crossref","first-page":"S999","DOI":"10.1016\/j.annonc.2024.08.1739","article-title":"1658TiP the STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: a phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)","volume":"35","author":"Padden-Modi","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2026.02.014_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1483953","article-title":"Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial","volume":"14","author":"Hansen","year":"2025","journal-title":"Front Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ucl.2026.02.014_bib60","first-page":"TPS256","article-title":"ProstACT GLOBAL: a phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug","volume":"42","author":"Hawkins","year":"2024","journal-title":"J Clin Orthod"},{"issue":"4_suppl","key":"10.1016\/j.ucl.2026.02.014_bib61","first-page":"TPS246","article-title":"SECuRE: a dose escalation\/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer","volume":"42","author":"Johnson","year":"2024","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ucl.2026.02.014_bib62","doi-asserted-by":"crossref","first-page":"S967","DOI":"10.1016\/j.annonc.2024.08.1685","volume":"35","author":"Yu","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib63","first-page":"5010","article-title":"First-in-human results of terbium-161[161Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase I\/II study","volume":"43","author":"Buteau","year":"2025","journal-title":"J Clin Orthod"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.02.014_bib64","first-page":"185","article-title":"Mature phase 1 follow up of alpha emitter 225Ac-J591 with 177Lu-PSMA-I&T in advanced prostate cancer","volume":"43","author":"Raab","year":"2025","journal-title":"J Clin Orthod"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.02.014_bib65","first-page":"TPS280","article-title":"AlphaBet: a phase I\/II trial evaluating the combination of radium-223 and [177Lu]Lu-PSMA-I&T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Kostos","year":"2023","journal-title":"J Clin Orthod"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.014_bib66","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","article-title":"How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer","volume":"24","author":"Stultz","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.014_bib67","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3390\/biom15060751","article-title":"Immune checkpoint inhibitor therapy for prostate cancer: present and future prospectives","volume":"15","author":"Rai","year":"2025","journal-title":"Biomolecules"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.014_bib68","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","article-title":"Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial","volume":"35","author":"van Wilpe","year":"2024","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ucl.2026.02.014_bib69","first-page":"18","article-title":"CONTACT-02: phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Agarwal","year":"2024","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ucl.2026.02.014_bib70","series-title":"Prostate cancer","article-title":"The usefulness of STEAP proteins in prostate cancer clinical practice","author":"Rocha","year":"2021"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.014_bib71","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1073\/pnas.95.4.1735","article-title":"Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer","volume":"95","author":"Reiter","year":"1998","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.014_bib72","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.014_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-53220-6","article-title":"PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial","volume":"15","author":"Stein","year":"2024","journal-title":"Nat Commun"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib74","first-page":"2536","article-title":"Updated results on the bispecific PSMAxCD3 antibody CC-1 for treatment of prostate cancer","volume":"42","author":"Heitmann","year":"2024","journal-title":"J Clin Orthod"},{"issue":"23","key":"10.1016\/j.ucl.2026.02.014_bib75","first-page":"00043-5","article-title":"Phase 1 Study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer","volume":"S1558-7673","author":"Lim","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.014_bib76","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human Study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib77","first-page":"TPS5118","article-title":"Trial in progress (XALute): phase 3 study of xaluritamig vs investigator\u2019s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Kelly","year":"2025","journal-title":"J Clin Orthod"},{"issue":"22","key":"10.1016\/j.ucl.2026.02.014_bib78","first-page":"2515","article-title":"Pasritamig, a First-in-Class, bispecific T-Cell engager targeting Human Kallikrein 2, in metastatic castration-resistant prostate cancer: a phase I study","volume":"43","author":"Stein","year":"2025","journal-title":"J Clin Orthod"},{"issue":"4_suppl","key":"10.1016\/j.ucl.2026.02.014_bib79","first-page":"TPS242","article-title":"LORIKEET: a phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Subudhi","year":"2024","journal-title":"J Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib80","first-page":"5012","article-title":"Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Orthod"},{"issue":"4_suppl","key":"10.1016\/j.ucl.2026.02.014_bib81","first-page":"121","article-title":"Interim results from a phase 1\/2 study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN)","volume":"42","author":"Beltran","year":"2024","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ucl.2026.02.014_bib82","doi-asserted-by":"crossref","first-page":"S984","DOI":"10.1016\/j.annonc.2024.08.1712","article-title":"1631P results from the quick efficacy seeking trial (QuEST1) arm combining BN-brachyury (BNVax) + bintrafusp alfa (BA) + nogapendekin alfa inbakicept-pmln (N-803) in castration-resistant prostate cancer (CRPC)","volume":"35","author":"Redman","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2026.02.014_bib83","doi-asserted-by":"crossref","first-page":"S974","DOI":"10.1016\/j.annonc.2023.09.2752","article-title":"1804P APEX-01: first-In-human phase I\/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"34","author":"Shen","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2026.02.014_bib84","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.trecan.2024.05.003","article-title":"B7-H3: a robust target for immunotherapy in prostate cancer","volume":"10","author":"Pulido","year":"2024","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.014_bib85","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","article-title":"B7-H3 as a therapeutic target in advanced prostate cancer","volume":"83","author":"Guo","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.014_bib86","doi-asserted-by":"crossref","first-page":"S744","DOI":"10.1016\/j.annonc.2022.07.582","article-title":"453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: extended follow-up of a phase I\/II study","volume":"33","author":"Doi","year":"2022","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib88","first-page":"5015","article-title":"DB-1311\/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC)","volume":"43","author":"Parsonson","year":"2025","journal-title":"J Clin Orthod"},{"issue":"8_Supplement_2","key":"10.1016\/j.ucl.2026.02.014_bib89","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-ND03","article-title":"Abstract ND03: ABBV-969: a first-in-class dual-targeting PSMA-STEAP1 drug conjugate for the treatment of metastatic castrate-resistant prostate cancer","volume":"85","author":"Reilly","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2026.02.014_bib90","doi-asserted-by":"crossref","first-page":"S1000","DOI":"10.1016\/j.annonc.2024.08.1741","article-title":"1660TiP first-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"35","author":"Berger","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.02.014_bib91","first-page":"3001","article-title":"Phase 1a\/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Aggarwal","year":"2022","journal-title":"J Clin Orthod"},{"issue":"10336","key":"10.1016\/j.ucl.2026.02.014_bib92","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.014_bib93","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:21:51Z","timestamp":1776446511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0094014326000145"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.014","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatments on the Horizon for Men with Advanced Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}